ALCMI and Biodesix Initiate Prospective Study to Predict Overall Survival Using Checkpoint Immunotherapy for Front-Line Lung Cancer in Patients with High PDL1 Expression
Addario Lung Cancer Medical Institute (ALCMI) and Biodesix, Inc. today announced they will begin an observational study to prospectively evaluate the clinical utility of biomarkers.
Biodesix, Inc. today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24.
Biodesix today announced the appointment of Jean Franchi and Hany Massarany to the company’s board of directors. Learn more!
Biodesix Pipeline Test Identifies Patients Who Are Likely to Respond to Immune Checkpoint Inhibitors
In the retrospective study, mass spectrometry-based proteomic analysis was performed on pretreatment sera derived from advanced NSCLC patients who were treated with nivolumab as part of routine clinical care.
Biodesix has launched the Biodesix WorkSafe™ Program, a customized return to work service for employers. Learn more about the testing program.
The data from these abstracts will be presented as e-posters at the virtual annual meetings of the American Thoracic Society (ATS), American Society of Clinical Oncology (ASCO), and American Association for Cancer Research (AACR).
The Biodesix SARS-CoV-2 ddPCR™ Test detects COVID-19 with greater sensitivity than other available tests, and is now accessible by appointment at drive-up locations in Boulder and Erie.
Biodesix Collaborates with Bio-Rad to Launch a Serology Test to Detect Coronavirus (COVID-19) Antibodies
Biodesix, Inc., a leading diagnostic company in lung disease, today announced that it has collaborated with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2, the virus that causes COVID-19.
Biodesix, Inc., a leading diagnostic company in lung disease, today announced that it began SARS-CoV-2 Droplet Digital PCR (ddPCR) testing for the virus that causes COVID-19 and will immediately submit for Emergency Use Authorization from the Food and Drug Administration.
Biodesix Partners with Bio-Rad to Bring Emergency Use Authorization (EUA) COVID-19 ddPCR™ Test to the U.S.
Biodesix, Inc., a leading diagnostic company in lung disease, today announced a partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to bring a COVID-19 Droplet Digital PCR (ddPCR) test to the FDA for an Emergency Use Authorization (EUA) approval to support the escalating need for testing in the U.S.